CV9201: Additional Phase I/IIa data

An open-label, Swiss and German Phase I/IIa trial in 31 evaluable stage IIIb/IV NSCLC patients who responded to or stabilized after first-line chemoradiotherapy showed that intradermal CV9201 was well...